SEARCH

SEARCH BY CITATION

References

  • 1
    National Diabetes Fact Sheet, 2007. Centers for Disease Control and Prevention [on-line]. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf Accessed December 10, 2010.
  • 2
    Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:19361940.
  • 3
    Brown AF, Mangione CM, Saliba D et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003;51(Suppl 5):S265S280.
  • 4
    American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care 2010;33(Suppl 1):S11S61.
  • 5
    UK Prospective Diabetes Study Group, UKPDS. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: A progressive disease. Diabetes 1995;44:12491258.
  • 6
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837853.
  • 7
    Wright A, Burden ACF, Paisey RB et al.; for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330336.
  • 8
    Perez N, Moisan J, Sirois C et al. Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs. Can Med Assoc J 2009;180:13101316.
  • 9
    Donnan PT, Steinke DT, Newton RW et al. Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: A population-based study. Diabet Med 2002;19:606610.
  • 10
    Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S18S24.
  • 11
    Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy: The basis of patient reluctance. Diabetes Care 1997;20:292298.
  • 12
    Brunton S, Carmichael B, Funnell M et al. Type 2 diabetes: The role of insulin. J Fam Pract 2005;54:445452.
  • 13
    Papa G, Fedele V, Chiavetta A et al. Therapeutic options for elderly diabetic subjects: Open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008;45:5359.
  • 14
    Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23(5):644649.
  • 15
    Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:30803086.
  • 16
    Massi Benedetti M, Humburg E, Dressler A et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189196.
  • 17
    Fritsche A, Schweitzer MA, Häring H-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2003;138:952959.
  • 18
    Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006;49:442451.
  • 19
    Bretzel RG, Nuber U, Landgraf W et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008;371:10731084.
  • 20
    Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254259.
  • 21
    Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs 1998;55(Suppl 1):1016.
  • 22
    Pan CY, Sinnassamy P, Chung KD et al. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 2007;76:111118.
  • 23
    Eliaschewitz FG, Calvo C, Valbuena H et al. Therapy in type 2 diabetes: Insulin glargine versus NPH insulin both in combination with glimepiride. Arch Med Res 2006;37:495501.
  • 24
    Kawamori R. Efficacy and safety of insulin glargine in concurrent use with oral hypoglycaemic agents for the treatment of type 2 diabetes patients. Rinsho Iyaku 2003;19:445464.
  • 25
    Bazzano LA, Lee LJ, Shi L et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: A meta-analysis of randomized controlled trials. Diabet Med 2008;25:924932.
  • 26
    Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950955.
  • 27
    Rosenstock J, Riddle MC. Insulin therapy in type 2 diabetes. In: Cefalu WT, Gerich JE, LeRoith D, ed. The CADRE Handbook of Diabetes Management. New York: Medical Information Press. 2004, pp 145168.
  • 28
    Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention. Drugs Aging 2004;21:511530.
  • 29
    Siderowf A. Parkinson's disease: Clinical features, epidemiology and genetics. Neurol Clin 2001;19:565578, vi.
  • 30
    Abraira C, Colwell JA, Nuttall FQ et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial. Diabetes Care 1995;18:11131123.
  • 31
    Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182188.
  • 32
    Grossman SP. The role of glucose, insulin and glucagon in the regulation of food intake and body weight. Neurosci Biobehav Rev 1986;10:295315.
  • 33
    Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:29482961.
  • 34
    Blettner M, Sauerbrei W, Schlehofer B et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999;28:19.
  • 35
    Mooradian AD, Bernbaum M, Albert SG. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med 2006;145:125134.
  • 36
    Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep 2004;119:263270.
  • 37
    Lee PG, Cigolle C, Blaum C. The co-occurrence of chronic diseases and geriatric syndromes: The Health and Retirement Study. J Am Geriatr Soc 2009;57:511516.
  • 38
    Matyka K, Evans M, Lomas J et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997;20:135141.
  • 39
    Dharmarajan TS, Russell RO, Dabhi K. Recurrent, refractory hypoglycemia presenting as a behavioral disorder in an older woman. J Am Geriatr Soc 1999;47:380381.
  • 40
    Kumari J, Dharmarajan TS. Insulin glargine induced persistent intractable hypoglycemia, with variable presentations in older diabetic patients: An experience of 4 cases. J Am Med Dir Assoc 2009;10:672673.